# Hims & Hers Stock Rallies as White House Reviews Peptide Compounding Rules

- URL: https://stocks.freetheai.org/news/hims-hers-stock-rallies-as-white-house-reviews-peptide-compounding-rules-6da509
- Published: 2026-10-16T02:04:19Z
- Category: regulation; sentiment: bullish; impact: medium
- Symbols: [NYSE:HIMS](https://stocks.freetheai.org/symbols/NYSE-HIMS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shares of Hims & Hers Health, Inc. (HIMS) rose nearly 6% to $29.38 on Thursday, snapping a three-day losing streak. The stock moved higher following news that the White House has begun reviewing a regulatory proposal that would temporarily ease restrictions on specialty pharmacy compounding for certain peptides, such as BPC-157. Despite the daily gain, the stock remains down about 5% for the week and 10% year-to-date.

The proposed interim access policy would allow pharmacies to compound unapproved peptides under enforcement discretion while formal FDA rulemaking proceeds. Analysts estimate that broader regulatory permission could open a $2.2 billion annual telehealth market, with Hims & Hers Health, Inc. potentially capturing $440 million in annual revenue. The company has actively prepared for this opportunity by acquiring a manufacturing plant in Menlo Park, California, and beginning stability testing on active pharmaceutical ingredients.

Investors are watching for formal adoption of the policy by the White House, as well as an official implementation schedule. Further attention will center on how quickly Hims & Hers Health, Inc. can complete testing, establish clinical guidelines, and launch supervised peptide offerings for consumers.

## Key points

- Hims & Hers Health, Inc. (HIMS) shares gained nearly 6% to $29.38, ending a three-day losing streak.
- The White House is reviewing an interim policy proposal that would allow compounding of peptides like BPC-157.
- Broader regulatory approval could open a $2.2 billion market, with Hims potentially earning $440 million annually.
- The company acquired a California manufacturing plant to support testing, clinical protocols, and product launches.

## Questions and answers

### Why did Hims & Hers Health stock rise on Thursday?

Shares gained nearly 6% after a proposed policy reached White House review that would allow specialty pharmacies to temporarily produce certain peptides, including BPC-157.

### How big is the potential market for compounded peptides?

Industry estimates suggest that opening regulatory access to reviewed peptides could create a $2.2 billion annual telehealth market, with Hims potentially capturing about $440 million in yearly sales.

### How is Hims preparing for peptide sales?

The company acquired a manufacturing facility in Menlo Park, California, in early 2025 and is conducting testing on active ingredients while developing clinical guidance and provider training.